- Chimeric Therapeutics (CHM) is granted a Japanese patent for its CLTX CAR technology
- With the patent in hand, Chimeric holds a worldwide license to develop and commercialise this patent and related patent applications filed in other global territories
- The company says the granting of this patent continues to expand the robust intellectual property portfolio underpinning its pipeline assets
- Chimeric will continue to further develop its oncology pipeline with new and novel cell therapy assets
- Chimeric Therapeutics is trading steady at 12.5 cents at 10:51 am AEST
Chimeric Therapeutics (CHM) has been granted a Japanese patent for its CLTX CAR technology.
The clinical-stage cell therapy company was issued the patent, entitled ‘Chimeric antigen receptors containing a chlorotoxin domain,’ which covers certain applications of the chimeric antigen receptor (CAR) technology using chlorotoxin (CLTX), including Chimeric’s CHM 1191 asset.
CHM 1101 (CLTX CAR T) is a therapy developed to treat patients with solid tumours. The drug is currently being studied in a phase one clinical trial in recurrent and progressive glioblastoma.
With the patent in hand, Chimeric holds a worldwide license to develop and commercialise this patent and related patent applications filed in other global territories.
“We are delighted to have patent protection granted for CLTX CAR therapies in Japan, the third largest pharmaceutical market in the world,” CEO and Managing Director Jennifer Chow said.
“The granting of this key Japan patent continues to expand the robust intellectual property portfolio underpinning our CLTX CAR pipeline assets.”
The company said it will continue to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets.
Chimeric Therapeutics was trading steady at 12.5 cents at 10:51 am AEST.